Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment

Curr Oncol Rep. 2014 Oct;16(10):407. doi: 10.1007/s11912-014-0407-z.

Abstract

Colorectal cancer is a common malignancy and often presents with synchronous or metachronous distant spread. For patients with hepatic metastases, resection is the principal curative option. Liberalization of the indications for hepatic resection has introduced a number of challenges related to the size, distribution, and number of metastases as well as the condition of the future liver remnant. Advances in systemic therapy have solidified its role as both an important adjunct to surgery and also for many patients as a mechanism to facilitate resection. In patients whose disease is marginally resectable as a consequence of the distribution of hepatic lesions that precludes complete resection or out of concern for the future liver remnant, a number of strategies have been advocated, including prehepatectomy systemic therapy, staged surgical approaches, ablative technologies, and preoperative portal vein embolization. It is the purpose of this review to discuss ways in which to optimize the treatment of patients with potentially resectable disease, specifically those who are judged to have "borderline" resectable situations.

Publication types

  • Review

MeSH terms

  • Chemoradiotherapy, Adjuvant / methods
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / therapy*
  • Embolization, Therapeutic
  • Evidence-Based Medicine
  • Hepatectomy / methods
  • Humans
  • Liver / pathology
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy*
  • Neoadjuvant Therapy / methods*
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Recurrence, Local / prevention & control
  • Neoplasm Staging
  • Practice Guidelines as Topic
  • Preoperative Care / methods
  • Prognosis
  • Treatment Outcome
  • Tumor Burden